EMA Presses On With Guidance On Secondary Use Of Health Data
The European Medicines Agency will use feedback from two workshops in September to clarify what data protection issues must be addressed to allow for the secondary use of health and medical data when it comes to developing, monitoring and evaluating medicines.
You may also be interested in...
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.